Metabolic Genetics and Therapeutics: Pillar Guide

Short version. Metabolic genetics has two intertwined literatures. The first, the inborn errors of metabolism, traces enzyme deficiencies through pathway-block reasoning that Archibald Garrod set out in 1902 and that Beadle and Tatum systematised four decades later as one-gene-one-enzyme. The second, pharmacogenetics, asks the inverse question — how heritable variation in metabolising enzymes shapes individual response to small-molecule drugs — and was named by Friedrich Vogel in 1959 and consolidated by Werner Kalow in 1962. Both literatures have, over the past two decades, fed into a therapeutic stack that now includes recombinant enzyme-replacement, AAV-delivered gene therapy, antisense oligonucleotides, ex vivo gene-modified cell therapies, and CRISPR-derived genome editing. This page is a structured introduction for students, researchers, and educators; the two subtopic pages below carry the detailed reference content.

A pathway view of the gene-to-phenotype relationship

The defining intuition of metabolic genetics is that genes encode catalysts — enzymes, transporters, cofactor-handling proteins — whose absence or impairment redirects flux through a metabolic pathway. Substrate accumulates upstream of a block; product is depleted downstream; alternative-pathway intermediates may rise as compensation; and the resulting phenotype is the pleiotropic consequence of all three. The pathway-block model is the cleanest mechanistic story human genetics has on offer: a missense or loss-of-function variant in a single gene produces a specific, biochemically traceable, often diet-modifiable disease.

The model originated with Sir Archibald Garrod's 1902 Lancet paper "The incidence of alkaptonuria: a study in chemical individuality" (Garrod 1902) and was elaborated in his 1923 monograph Inborn Errors of Metabolism. Garrod observed that patients with alkaptonuria excreted homogentisic acid in urine that darkened on standing, that the trait clustered in sibships from consanguineous unions, and that this was consistent with the pattern Mendel had described in peas. He inferred — without yet having a molecular framework — that an inherited factor was producing a specific biochemical lesion. Forty years later, working with Neurospora crassa, George Beadle and Edward Tatum showed that single mutations produced single nutritional auxotrophies, supplying the synthesis Garrod had anticipated: each gene specifies the structure of one enzyme (Beadle and Tatum 1941, PNAS 27:499). The one-gene-one-enzyme principle, later refined to one-gene-one-polypeptide, is the conceptual scaffold on which the modern catalogue of inborn errors of metabolism is built.

Inborn errors of metabolism: the catalogue today

The contemporary catalogue, codified in references such as Saudubray, Baumgartner and Walter's Inborn Metabolic Diseases (Springer, 6th edition 2016) and the OMIM database, contains more than a thousand recognised disorders, organised by the metabolic pathway each disrupts. The major groups are amino-acid disorders (phenylketonuria, tyrosinaemia, maple syrup urine disease, homocystinuria); urea-cycle defects (ornithine transcarbamylase deficiency, citrullinaemia, argininosuccinic aciduria, arginase deficiency); organic acidaemias (methylmalonic, propionic, isovaleric); fatty acid oxidation defects (medium-chain, long-chain, and very-long-chain acyl-CoA dehydrogenase deficiencies); lysosomal storage disorders (Tay-Sachs, Gaucher, Fabry, Pompe, the mucopolysaccharidoses, Niemann-Pick); peroxisomal disorders (X-linked adrenoleukodystrophy, the Zellweger spectrum); the mitochondrial disorders (MELAS, MERRF, LHON, Leigh, NARP, Kearns-Sayre — treated separately under mitochondrial inheritance on this site because their non-Mendelian transmission is what counts in pedigree analysis); the glycogen storage diseases (von Gierke, Pompe, McArdle); and the congenital disorders of glycosylation. The full structured introduction is on the inborn errors of metabolism subtopic page.

Two practical features distinguish this catalogue. First, much of it is tractable to early detection: phenylketonuria, identified by Robert Guthrie's bacterial inhibition assay in 1963, was the first disease for which heel-prick newborn screening became a population programme (Guthrie and Susi 1963). Modern newborn screening panels now use tandem mass spectrometry to detect more than thirty acylcarnitine and amino-acid analytes from a single dried blood spot — the UK NHS programme and the US Recommended Uniform Screening Panel are the two most widely cited reference panels. Second, where direct enzyme assay or biochemical screening is unrevealing, exome sequencing has become a productive next step; Yang et al. 2013, NEJM 369:1502 reported a 25 percent diagnostic yield in 250 unselected patients referred for clinical exome sequencing, with metabolic and neurodevelopmental phenotypes well represented.

Pharmacogenetics: the inverse question

If inborn errors of metabolism ask how a missing enzyme rearranges a metabolic landscape, pharmacogenetics asks the inverse: when an exogenous small molecule enters that landscape, how does heritable variation in the metabolising enzymes shape its kinetics and effects? Friedrich Vogel coined the term in 1959 (Acta Genetica 9:312) after a sequence of post-war observations — pseudocholinesterase deficiency and prolonged paralysis after suxamethonium, primaquine-induced haemolysis in G6PD-deficient soldiers, and slow versus rapid acetylation of isoniazid — that pointed at the same hypothesis. Werner Kalow's 1962 textbook Pharmacogenetics: Heredity and the Response to Drugs consolidated the field; the canonical pharmacogenetic axes Kalow identified — NAT2 acetylator status, butyrylcholinesterase variants, G6PD genotype — are still part of the modern syllabus.

What changed in the genomic era was the volume and granularity of the cytochrome P450 phenotype maps. CYP2D6, CYP2C19, CYP2C9, CYP3A4, and CYP3A5 between them metabolise a substantial fraction of marketed small-molecule drugs, and each carries common variants whose effects on substrate clearance have been mapped in detail. Codeine bioactivation depends on CYP2D6 O-demethylation to morphine; ultrarapid metabolisers convert more aggressively. Clopidogrel requires CYP2C19 for activation; loss-of-function variants reduce the active metabolite. Warfarin dosing tracks both CYP2C9 (S-warfarin clearance) and VKORC1 (target sensitivity). The HLA literature identifies associations such as HLA-B*57:01 with abacavir hypersensitivity (Mallal et al. 2008, NEJM 358:568) and HLA-B*15:02 with carbamazepine cutaneous reactions in some Asian populations. Thiopurine methyltransferase (TPMT) and NUDT15 variants raise the risk of cytopenia on standard thiopurine doses; UGT1A1 variants on irinotecan; DPYD on 5-fluorouracil. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published structured guideline documents for each of these gene-drug pairs (Caudle et al. 2014, Clin Pharmacol Ther 96:542), and the Pharmacogenomics Knowledge Base (PharmGKB) curates the evidence base. Detail is on the pharmacogenetics subtopic page.

From mechanistic understanding to therapeutic strategies

The therapeutic stack that has grown out of these two literatures has, in the past decade, become extensive enough to be hard to summarise without a taxonomy. Five categories help.

Substrate restriction and product supplementation have been the workhorses for inborn errors of metabolism for fifty years — phenylalanine-restricted diet for PKU, protein-restricted regimens with nitrogen-scavenger drugs for urea-cycle defects, fat-modified regimens for fatty acid oxidation defects, mannose for MPI-CDG. These are mechanistically motivated by the pathway-block model and remain first-line for many disorders.

Recombinant enzyme replacement therapy delivers a missing enzyme as a periodic infusion. Imiglucerase for type 1 Gaucher (1991) was the prototype; alglucosidase alfa for Pompe, agalsidase alfa and beta for Fabry, and laronidase, idursulfase, elosulfase, galsulfase, and vestronidase for the mucopolysaccharidoses followed. The reach of enzyme-replacement therapy is bounded by where the recombinant protein can get to — central-nervous-system disorders are the standing limitation.

Substrate-reduction therapy uses small molecules to slow upstream synthesis when downstream catabolism is impaired (miglustat and eliglustat for Gaucher; migalastat as a chaperone for amenable Fabry variants). Antisense oligonucleotides modulate splicing or transcript stability: nusinersen (Spinraza) restores SMN2 exon 7 inclusion in spinal muscular atrophy (Finkel et al. 2017, NEJM 377:1723).

Adeno-associated virus (AAV) gene therapy delivers a functional copy of a gene to non-dividing cells. Voretigene neparvovec (Luxturna) for RPE65-associated Leber congenital amaurosis (Russell et al. 2017, Lancet 390:849) and onasemnogene abeparvovec (Zolgensma) for SMN1-deficient SMA (Mendell et al. 2017, NEJM 377:1713) are the published archetypes.

Genome editing rewrites the genome itself. The CRISPR-Cas9 platform (Jinek et al. 2012, Science 337:816; Doudna and Charpentier 2014, Science 346:1258) was extended in 2016 by base editing (Komor et al. 2016, Nature 533:420) and in 2019 by prime editing (Anzalone et al. 2019, Nature 576:149). The 2023 approvals of exa-cel (Casgevy) for sickle cell disease and transfusion-dependent β-thalassaemia, building on the published trial data of Frangoul et al. 2021, NEJM 384:252, marked the entry of CRISPR-derived editing into the published therapeutic literature.

How this pillar is structured

The two subtopic pages divide the field along the historical Garrod / Vogel split. Inborn errors of metabolism covers enzyme defects and pathway-block reasoning, the major disease groups, newborn screening, and the role of exome sequencing in the diagnostic odyssey. Pharmacogenetics and emerging therapeutics covers drug-metabolising enzyme variation, the canonical gene-drug pairs codified by CPIC, and the therapeutic stack from AAV gene therapy through CRISPR-derived editing.

Both pages are written for students, researchers, and educators — not as clinical decision support and not as patient-facing medical information. Where they reference specific approved therapies, they do so as published research-literature reports of trial outcomes, with citations to the canonical papers. They are not recommendations, and should not be read as such. Genetic testing and therapeutic decisions belong with a qualified clinical-genetics or pharmacology service.

Where pedigrees fit

For inborn errors of metabolism, family-history documentation matters because most are autosomal recessive (with the urea-cycle disorder OTC and the X-linked adrenoleukodystrophy as notable exceptions, both X-linked). Carrier identification, consanguinity, ethnic-group variant frequencies (Tay-Sachs in Ashkenazi Jewish families; sickle cell in West African and Afro-Caribbean families; thalassaemia across the Mediterranean and South Asia), and pre-pregnancy or antenatal counselling all benefit from a structured pedigree. Evagene's autosomal recessive calculator and consanguinity calculator are the closest tools on the platform. Mitochondrial disorders — many of which are metabolic in origin — are a separate category, modelled at mitochondrial inheritance pedigree.

Pharmacogenetic variation, by contrast, sits orthogonally to pedigree drawing in most workflows: it is genotype-by-genotype rather than family-by-family, and the relevant data is captured at the individual level rather than across a sibship. The pedigree's role in pharmacogenetics is mainly historical — discovering that suxamethonium-induced apnoea recurred in Kalow's families was how the field began — and educational, when introducing the inheritance of metabolising-enzyme variants to students.

Selected references

Garrod, A. E. (1902). The incidence of alkaptonuria: a study in chemical individuality. Lancet 160:1616–1620. DOI
Garrod, A. E. (1923). Inborn Errors of Metabolism (2nd edition). Henry Frowde and Hodder & Stoughton.
Beadle, G. W., and Tatum, E. L. (1941). Genetic control of biochemical reactions in Neurospora. PNAS 27:499–506. DOI
Guthrie, R., and Susi, A. (1963). A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32:338–343. PubMed
Vogel, F. (1959). Moderne Probleme der Humangenetik. Ergebnisse der Inneren Medizin und Kinderheilkunde 12:52–125 (term "Pharmakogenetik" introduced); Acta Genetica et Statistica Medica 9:312.
Kalow, W. (1962). Pharmacogenetics: Heredity and the Response to Drugs. W. B. Saunders.
Saudubray, J.-M., Baumgartner, M. R., and Walter, J. H. (eds.) (2016). Inborn Metabolic Diseases: Diagnosis and Treatment (6th edition). Springer.
Yang, Y. et al. (2013). Clinical whole-exome sequencing for the diagnosis of mendelian disorders. NEJM 369:1502–1511. PubMed
Caudle, K. E. et al. (2014). Incorporation of pharmacogenomics into routine clinical practice: the CPIC guideline development process. Clin Pharmacol Ther 96:542–548. PubMed
Frangoul, H. et al. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. NEJM 384:252–260. PubMed

Metabolic genetics and therapeutics